ImpediMed Limited Stock
Stocks
IPD
AU000000IPD8
Advanced Medical Equipment & Technology
OTC Markets Traded|
Market Closed -
Australian S.E.
06:24:28 17/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.005000 AUD | -9.09% |
|
0.00% | -85.29% |
| 08-27 | ImpediMed Limited Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 08-27 | ImpediMed Limited Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 18.31M 13.02M 11.35M 10.72M 9.73M 18.24M 1.25B 128M 49.55M 635M 48.9M 47.82M 2.04B | P/E 2027 * |
-1.61x | P/E 2028 * | -2.5x |
|---|---|---|---|---|---|
| Enterprise Value | 24.02M 17.08M 14.89M 14.06M 12.77M 23.92M 1.64B 168M 65M 833M 64.15M 62.73M 2.68B | EV / Sales 2027 * |
1.17x | EV / Sales 2028 * | 0.93x |
| Free-Float |
92.02% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| IPD | Delayed | |
OTC Markets
| IPDQF | Delayed | |
|
Deutsche Boerse AG
| R1J | Delayed |
Last Transcript: ImpediMed Limited
| 01-30 | Bell Potter rates IPD as Speculative Buy | AQ |
| 01-30 | Morgans rates IPD as Speculative Buy | AQ |
| 10/02/25 | ImpediMed Secures $15m Growth Capital Funding | AQ |
| 05/07/24 | Morgans rates IPD as Add | AQ |
| 01/05/24 | Ord Minnett rates IPD as Speculaitve Buy | AQ |
| 1 day | -9.09% | ||
| 3 months | -16.67% | ||
| 6 months | -68.75% | ||
| Current year | -85.29% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0.01 |
| Current year | 0 | | 0.04 |
| 1 year | 0 | | 0.06 |
| 3 years | 0 | | 0.2 |
| 5 years | 0 | | 0.24 |
| 10 years | 0 | | 1.74 |
| Manager | Title | Age | Since |
|---|---|---|---|
Erik Anderson
CEO | Chief Executive Officer | - | 07/04/2026 |
McGregor Grant
DFI | Director of Finance/CFO | - | 20/11/2023 |
Steven Chen
CTO | Chief Tech/Sci/R&D Officer | - | 26/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
McGregor Grant
CHM | Chairman | - | - |
| Chairman | - | 26/02/2024 | |
Janelle Delaney
BRD | Director/Board Member | - | 28/09/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/01/26 | Buy | Chairman | 146,408 | 0.0072% | ||
| 16/01/26 | Buy | Director | 100,563 | 0.0049% | ||
| 16/01/26 | Buy | Director | 100,563 | 0.0049% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.09% | 0.00% | -85.71% | -97.14% | 13.02M | |
| -1.04% | +6.83% | +35.41% | +28.31% | 243B | |
| -0.32% | +5.83% | +8.47% | -16.53% | 149B | |
| +2.55% | +6.55% | -9.75% | +31.91% | 135B | |
| -0.48% | +0.84% | -55.88% | -18.23% | 63.11B | |
| +0.01% | +4.61% | +18.39% | +21.00% | 50.87B | |
| -1.69% | -1.20% | -20.18% | -16.57% | 49.1B | |
| +0.08% | +6.49% | +22.61% | +38.85% | 44.08B | |
| -1.88% | +3.25% | +37.62% | +54.22% | 42.22B | |
| -2.27% | +16.07% | +132.57% | +68.26% | 37.02B | |
| Average | -1.41% | +5.76% | +8.35% | +9.41% | 81.47B | |
| Weighted average by Cap. | -0.28% | +6.11% | +15.31% | +17.65% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 20.56M 14.61M 12.74M 12.03M 10.93M 20.47M 1.4B 144M 55.61M 713M 54.89M 53.67M 2.29B | 27.58M 19.61M 17.1M 16.14M 14.66M 27.47M 1.88B 193M 74.62M 956M 73.65M 72.02M 3.08B |
| Net income | -12.84M -9.13M -7.96M -7.51M -6.82M -12.78M -876M -90.01M -34.73M -445M -34.28M -33.52M -1.43B | -6.26M -4.45M -3.88M -3.67M -3.33M -6.24M -427M -43.91M -16.94M -217M -16.72M -16.35M -699M |
| Net Debt | 5.71M 4.06M 3.54M 3.34M 3.03M 5.69M 389M 40.03M 15.45M 198M 15.25M 14.91M 637M | 7.39M 5.26M 4.58M 4.33M 3.93M 7.36M 504M 51.83M 20M 256M 19.74M 19.3M 825M |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/09/26 | A$0.005000 | -9.09% | 80,000 |
| 16/09/26 | A$0.005500 | +10.00% | 19,916 |
| 15/09/26 | A$0.005000 | 0.00% | 9,758,412 |
| 14/09/26 | A$0.005000 | 0.00% | 510,466 |
| 11/09/26 | A$0.005000 | 0.00% | 436,005 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IPD Stock
Select your edition
All financial news and data tailored to specific country editions
